CURE’s skin cancer page is an extensive resource of cancer information featuring the latest skin cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on skin cancer.
October 11th 2024
From Jenna Fischer announcing her breast cancer diagnosis to Martha Davis and the Motels canceling concerts after her radiation therapy, here’s what’s happening in the cancer space this week.
Combination Continues to Show Impressive Outcomes in Melanoma
November 3rd 2017In an interview with CURE, Postow, a medical oncologist specializing in melanoma at Memorial Sloan Kettering Cancer Center, discussed the impressive efficacy seen with combining BRAF and MEK inhibitors for patients with melanoma.
Drug Combination Granted FDA Breakthrough Designation for Melanoma Treatment
October 23rd 2017The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) was granted a breakthrough therapy designation by the Food and Drug Administration (FDA) for the adjuvant treatment of patients who have stage 3 melanoma and a BRAF V600 mutation, after they have already had a complete resection.
Immunotherapy Combination Sparks a Response in Melanoma Brain Metastases
October 23rd 2017The combination of the immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab) sparked a response in nearly half of asymptomatic patients with melanoma brain metastases who had not received prior local therapy to the brain.
Intralesional Combinations Are Promising in Melanoma
October 19th 2017Intralesional therapies – those delivered directly to the tumor site – used in conjunction with checkpoint inhibitors have shown improvements to the treatment of people with melanoma, says Robert Andtbacka, M.D., in a presentation at the 2017 World Congress of Melanoma.
Opdivo Granted Priority Review for Post-Surgical Melanoma Treatment
October 18th 2017Opdivo (nivolumab) was granted a priority review to a supplemental biologics license application (sBLA) to treat patients with melanoma who have a high risk of disease recurrence after complete surgical resection, according to Bristol-Myers Squibb (BMS), the company that makes the drug.
Drug Pair Benefits Patients With Melanoma Who Progressed on Prior Therapy
October 3rd 2017Combination therapy of Opdivo (nivolumab) and LAG-3 inhibitor relatlimab (BMS-986016) benefitted half of the patients with melanoma who previously progressed on an anti-PD-1 or anti-PD-L1 therapy, according to recent results from a dose-expansion study.
Drug Combination Improves Outcomes for Melanoma Subtype
September 20th 2017In a recent phase 2 study, nearly half of patients who had resectable stage 3B/C BRAF V600-mutant melanoma achieved pathologic complete response (pCR) – meaning that no active cancer cells are present – with neoadjuvant combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib).
Expert Urges Patients to Speak Up About Treatment Side Effects
September 19th 2017Jeffrey Weber, M.D., Ph.D., Deputy Director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses how important it is that patients speak up when they experience side effects from their cancer treatments.